FY2025 · ended Dec 31, 2025 · Revenue $125.58M, +13.7% YoY · Filed Feb 25, 2026
Xencor, Inc (XNCR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $125.6 million and a net loss of $91.9 million. Free cash flow was -$138.3 million. As of Sep 30, 2026 it held $555.7 million in cash and investments and $137.1 million in total debt.
Revenue (TTM)
$200.49M
+33.5% vs year-ago TTM
Net income (TTM)
$-117.86M
+9.9% vs year-ago TTM
Operating cash flow (TTM)
$-172.35M
-29.4% vs year-ago TTM
Free cash flow (TTM)
$-176.45M
-28.9% vs year-ago TTM
EPS (TTM)
$-1.56
+11.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
73.34M
+4.1% vs prior year
Net cash
$418.60M
as of Sep 30, 2026
Operating margin
-72.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XNCR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Pasadena, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1326732
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $125.6M | $110.5M | $174.6M | $164.6M | $275.1M |
| Operating income | -$177.5M | -$178.4M | -$132.4M | -$82.5M | $43.8M |
| Net income | -$91.9M | -$232.6M | -$133.1M | -$55.2M | $82.6M |
| Diluted EPS | -$1.24 | -$3.58 | -$2.20 | -$0.93 | $1.37 |
| Operating cash flow | -$135.1M | -$202.2M | -$77.9M | $24.5M | -$16.9M |
| Free cash flow | -$138.3M | -$208.3M | -$96.4M | -$14.0M | -$30.2M |
| Total assets | $875.5M | $951.9M | $965.1M | $846.3M | $838.2M |
| Total liabilities | $239.9M | $277.9M | $303.0M | $118.8M | $104.7M |
| Stockholders' equity | $635.6M | $677.6M | $661.8M | $727.5M | $733.5M |
| Cash and investments | $610.8M | $706.7M | $697.0M | $584.5M | $597.7M |
| Total debt | $144.5M | $183.5M | $224.2M | $59.6M | $34.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Oct 26, 2026 | Oct 25, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Regulation FD disclosure
|
Jul 29, 2026 | Jul 29, 2026 |
All 896 Xencor, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.